Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Achievement of the Primary Endpoint in the Interim Analysis of the Phase III Clinical Trial of T-Bren (HER2 ADC) for the Treatment of Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer After Failure of Trastuzumab and Taxane Therapy

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 ·

On 6ix: 6ix.com/news/688506sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-achievement-of-the-primary-endpoint-in-the-interim-analysis-of-the-phase-iii-clinical-trial-of-t-bren-her2-adc-for-the-treatment-of-unresectable-locally-advanced-or-metastatic-her2-positive-breast-cancer-after-failure-of-trastuzumab-and-taxane-therapy

Announcement on Voluntary Disclosure of Achievement of the Primary Endpoint in the Interim Analysis of the Phase III Clinical Trial of T-Bren (HER2 ADC) for the Treatment of Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer After Failure of Trastuzumab and Taxane Therapy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases